Apogee Therapeutics/$APGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Apogee Therapeutics
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Ticker
$APGE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
196
ISIN
US03770N1019
Website
APGE Metrics
BasicAdvanced
$2.4B
-
-$3.59
-
-
Price and volume
Market cap
$2.4B
52-week high
$50.56
52-week low
$26.20
Average daily volume
737K
Financial strength
Current ratio
15.823
Quick ratio
15.726
Long term debt to equity
1.164
Total debt to equity
1.755
Profitability
EBITDA (TTM)
-241.418
Effective tax rate (TTM)
-0.05%
Management effectiveness
Return on assets (TTM)
-19.65%
Return on equity (TTM)
-27.85%
Valuation
Price to book
3.57
Price to tangible book (TTM)
3.57
Price to free cash flow (TTM)
-12.195
Free cash flow yield (TTM)
-8.20%
Free cash flow per share (TTM)
-337.67%
Growth
Earnings per share change (TTM)
25.89%
Bulls say / Bears say
Citigroup initiated coverage of Apogee Therapeutics with a 'Buy' recommendation and a price target suggesting a 144.31% upside, indicating strong confidence in the company's growth potential. (nasdaq.com)
Apogee Therapeutics has initiated a Phase 1 trial for APG990, a drug developed for atopic dermatitis, with interim data expected in 2025, showcasing progress in its clinical pipeline. (investing.com)
The company maintains a strong financial position with $790 million in assets, expected to support the continued development of its pipeline into 2028, providing a solid foundation for future growth. (investing.com)
The CEO of Apogee Therapeutics sold over $1.9 million in stock, which could be perceived negatively by investors as a lack of confidence in the company's future prospects. (investing.com)
Apogee Therapeutics reported an annual income of -$182.15 million, indicating significant losses that may concern investors about the company's profitability. (barchart.com)
The company's earnings per share (EPS) for the trailing twelve months is -3.29, reflecting ongoing financial challenges that could impact investor sentiment. (barchart.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
APGE News
AllArticlesVideos
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
GlobeNewsWire·1 month ago
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apogee Therapeutics stock?
Apogee Therapeutics (APGE) has a market cap of $2.4B as of June 20, 2025.
What is the P/E ratio for Apogee Therapeutics stock?
The price to earnings (P/E) ratio for Apogee Therapeutics (APGE) stock is 0 as of June 20, 2025.
Does Apogee Therapeutics stock pay dividends?
No, Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Apogee Therapeutics dividend payment date?
Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Apogee Therapeutics?
Apogee Therapeutics (APGE) does not currently have a Beta indicator.